Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

NCT07722741 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

HCC

Interventions

BIOLOGICAL: GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation
DEVICE: Electroporation Device
BIOLOGICAL: INO-9012

Sponsor

Geneos Therapeutics